Medical Oncology

Uzm. Dr. Taliha Güçlü Kantar

Doctor and researcher Denizli Devlet Hastanesi Denizli
Breast NeoplasmsLung Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 3 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Lung Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionDenizli Devlet Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 3 publications · Model version —From source
  • Publications33 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-7836-4272ORCIDFrom source
  • Last synchronised5 November 2026 07:59https://denizlidh.saglik.gov.tr/TR-641564/doktorlarimiz.html#taliha-guclu-kantarsaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

33 publications

  1. Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16868-5 Open-access full textSource: OpenAlex

  2. Prognostic Value of Systemic Inflammatory Markers in Locally Advanced or Metastatic Melanoma: A Real-World Analysis

    Cancers, 2026

    DOI 10.3390/cancers18030420 PMID 41681891 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  3. Differential Metastatic Patterns and Prognostic Value of Systemic Inflammation Scores in Anaplastic Lymphoma Kinase Rearranged Versus Anaplastic Lymphoma Kinase Negative Non-Small Cell Lung Cancer

    Cancers, 2026

    DOI 10.3390/cancers18030501 PMID 41681973 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  4. Meme Kanseri

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852 Open-access full textSource: OpenAlex

  5. Inflammation-tumor burden interaction score stratifies survival after irinotecan-eluting bead chemoembolization for colorectal liver metastases

    Frontiers in Medicine, 2026

    DOI 10.3389/fmed.2026.1751660 PMID 41907246 Open-access full textSource: OpenAlex

  6. Prevalence and Prognostic Significance of Positron Emission Tomography–Computed Tomography–Defined Low Skeletal Muscle Mass (Radiological Sarcopenia) in Metastatic Breast Cancer

    Cerrahpaşa Medical Journal, 2026

    DOI 10.5152/cjm.2026.26112 Open-access full textSource: ORCID

  7. Prognostic Role of Inflammatory Indices and Real-World Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine

    Diagnostics, 2026

    DOI 10.3390/diagnostics16111746 PMID 42279613 Open-access full textSource: ORCID

  8. The Royal Marsden Hospital Score Independently Predicts Overall Survival in Patients with De Novo Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors: A Multicenter Retrospective Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15103613 PMID 42194578 Open-access full textSource: ORCID

  9. Association of Increased Cardio-Ankle Vascular Index (CAVI) with Echocardiographically Impaired Diastolic Dysfunction and Low Klotho Levels in Kidney Transplant Patients

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15072727 PMID 41977028 Open-access full textSource: ORCID

  10. On-treatment dNLR and metastatic burden predict survival in advanced non-small-cell lung cancer treated with nivolumab

    Turkish Journal of Clinics and Laboratory, 2026

    DOI 10.18663/tjcl.1849630 Open-access full textSource: ORCID

View all 33 publications